Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
NCT07033598Phase 2Recruiting
- Sponsor
- Theradex Oncology
- Start
- Jan 2026
- Primary completion
- Jul 2028
- Countries
- 2
01
Overview
A Phase 2 trial of pacritinib in chronic myelomonocytic leukemia (CMML), sponsored by Theradex Oncology. Started Jan 2026; status: recruiting.
02
Drugs
pacritinib
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT07033598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033598.